EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY

被引：0
|
作者：
Liu-Walsh, F. [1 ]
Hartingsveldt, B. V. [2 ]
Zuraw, Q. [1 ]
Hoffman, R. W. [1 ]
Rooney, T. [1 ]
Gao, S. [1 ]
Karpouzas, G. [3 ,4 ]
Gordon, R. [1 ]
Leu, J. H. [1 ]
Calderon, C. [1 ]
Zazzetti, F. [5 ]
Stevens, A. M. [1 ]
Vratsanos, G. [1 ]
机构：
[1] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[2] Janssen Biol Europe, Clin Therapeut, Leiden, Netherlands
[3] Harbor UCLA Med Ctr, Div Rheumatol, Torrance, CA USA
[4] Lundquist Inst, Torrance, CA USA
[5] Janssen Cilag Argentina, Immunol Global Med Affairs, Buenos Aires, DF, Argentina
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Systemic lupus erythematosus; Safety; Autoantibodies;
D O I：
10.1136/annrheumdis-2023-eular.2219
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0548
引用
收藏
页码：1472 / 1473
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF NIPOCALIMAB IN ADULT PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: DESIGN OF A PHASE 2 STUDY
    Liu-Walsh, Fang
    van Hartingsveldt, Bart
    Zuraw, Qing
    Hoffman, Robert W.
    Rooney, Terence
    Gao, Sheng
    Bravo Perdomo, Ana Maria
    Gordon, Robert
    Leu, Jocelyn H.
    Calderon, Cesar
    Zazzetti, Federico
    Stevens, Anne M.
    Vratsanos, George
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S59 - S60
  • [2] Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
    Urowitz, Murray B.
    Isenberg, David A.
    Wallace, Daniel J.
    [J]. LUPUS SCIENCE & MEDICINE, 2015, 2 (01):
  • [3] EFFICACY AND SAFETY OF RITUXIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Ren, Y.
    Wang, L.
    An, Z.
    Yang, L.
    Su, Q. Y.
    Yu, Q.
    He, P. F.
    Li, X.
    Zhang, S. X.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1477 - 1477
  • [4] Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
    Brunner, Hermine, I
    Abud-Mendoza, Carlos
    Mori, Masaaki
    Pilkington, Clarissa A.
    Syed, Reema
    Takei, Syuji
    Viola, Diego O.
    Furie, Richard A.
    Navarra, Sandra
    Zhang, Fengchun
    Bass, Damon L.
    Eriksson, Gina
    Hammer, Anne E.
    Ji, Beulah N.
    Okily, Mohamed
    Roth, David A.
    Quasny, Holly
    Ruperto, Nicolino
    [J]. RMD OPEN, 2021, 7 (03):
  • [5] Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study
    van Vollenhoven, Ronald F.
    Hahn, Bevra H.
    Tsokos, George C.
    Lipsky, Peter
    Gordon, Robert M.
    Fei, Kaiyin
    Lo, Kim Hung
    Chevrier, Marc
    Rose, Shawn
    Berry, Pamela
    Yao, Zhenling
    Karyekar, Chetan S.
    Zuraw, Qing
    [J]. JOURNAL OF RHEUMATOLOGY, 2022, 49 (04) : 380 - 387
  • [6] Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study
    Merrill, Joan
    Werth, Victoria
    Furie, Richard
    van Vollenhoven, Ronald
    Majdan, Maria
    Weiswasser, Michael
    Korish, Shimon
    Liu, Zhaohui
    Schafer, Peter
    Delev, Nikolay
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3059 - 3062
  • [7] Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
    Merrill, Joan
    Werth, Victoria
    Furie, Richard
    van Vollenhoven, Ronald
    Petronijevic, Milan
    Velasco Zamora, Benito
    Majdan, Maria
    Irazoque-Palazuelos, Fedra
    Weiswasser, Michael
    Korish, Shimon
    Schafer, Peter
    Liu, Zhaohui
    Gaudy, Allison
    Agafonova, Nataliya
    Delev, Nikolay
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [8] Efficacy and safety data of belimumab in patients with systemic lupus erythematosus
    Shakoory, Bita
    Clatham, Winn
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (03) : 159 - 164
  • [9] Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus
    Iaccarinol, Luca
    Saccon, Francesca
    Mathieu, Alessandro
    Piga, Matteo
    Ceribelli, Angela
    Selmi, Carlo
    Cardinaletti, Paolo
    Gabrielli, Armando
    Di Matteo, Andrea
    De Angelis, Rossella
    Faggioli, Paola
    Laria, Antonella
    Fredi, Micaela
    Regola, Francesca
    Tincani, Angela
    Andreoli, Laura
    Pazzola, Giulia
    Salvarani, Carlo
    Puppo, Francesco
    Magnani, Ottavia
    Prete, Marcella
    Gremese, Elisa
    Gerosa, Maria
    Ubiali, Tania
    Bozzolo, Enrica
    Canti, Valentina
    Racanelli, Vito
    Conti, Fabrizio
    Ceccarelli, Fulvia
    Bartoloni, Elena
    Gerli, Roberto
    Lobasso, Antonio
    de Paulis, Amato
    De Marchi, Ginevra
    De Vita, Salvatore
    Bortoluzzi, Alessandra
    Govoni, Marcello
    Benvenuti, Francesco
    Zen, Margherita
    Mosca, Marta
    Tani, Chiara
    Rossini, Maurizio
    Orsolini, Giovanni
    Scarpato, Salvatore
    Brunetta, Ernico
    Zumbo, Aurora
    Tanti, Giacomo
    Doria, Andrea
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [10] Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
    Navarra, Sandra V.
    Guzman, Renato M.
    Gallacher, Alberto E.
    Hall, Stephen
    Levy, Roger A.
    Jimenez, Renato E.
    Li, Edmund K-M
    Thomas, Mathew
    Kim, Ho-Youn
    Leon, Manuel G.
    Tanasescu, Coman
    Nasonov, Eugeny
    Lan, Joung-Liang
    Pineda, Lilia
    Zhong, Z. John
    Freimuth, William
    Petri, Michelle A.
    [J]. LANCET, 2011, 377 (9767): : 721 - 731
12345